The next generation of weight management peptides. A triple agonist targeting GLP-1, GIP, and glucagon receptors simultaneously — with Phase II data showing up to 24% body weight reduction.
Retatrutide activates three receptors: GLP-1 (appetite suppression, insulin secretion), GIP (metabolic efficiency, lipid metabolism), and glucagon (hepatic fat mobilization, energy expenditure). The glucagon component is the key differentiator — it increases energy expenditure and promotes liver fat clearance, adding a thermogenic dimension absent from GLP-1-only and dual agonist therapies.
Phase II data showed the highest weight reduction of any peptide therapy (up to 24%), making it particularly relevant for women with treatment-resistant obesity or severe metabolic dysfunction. The glucagon component may also benefit non-alcoholic fatty liver disease (NAFLD), which increases in prevalence after menopause. Currently in Phase III trials with potential approval on the horizon.
GI side effects similar to other incretin therapies (nausea, vomiting, diarrhea) but potentially more pronounced due to triple agonism. Phase III safety data is still being collected. As an investigational compound, long-term safety profile is not yet established.
No. Retatrutide is currently in Phase III clinical trials and is classified as an investigational compound. It is not yet approved for any indication. Availability through research peptide vendors is for research purposes.
Retatrutide adds glucagon receptor activation on top of GLP-1/GIP, potentially providing greater weight loss and liver fat clearance. Phase II data showed up to 24% weight reduction vs tirzepatide's 22.5%. Head-to-head trials have not been conducted.
Part of our Weight Management hub.
Medical Disclaimer: This profile is for educational purposes only. Always consult a licensed healthcare provider before starting any peptide therapy.
Affiliate Disclosure: Vendor links are affiliate partnerships. Full disclosure →
Take our 60-second quiz for a personalized recommendation.
Find Your Peptide →